middle.news
TrivarX Appoints Experienced CEO to Accelerate Stabl-Im Brain Cancer Trials
9:04am on Wednesday 29th of April, 2026 AEST
•
Healthcare
Read Story
TrivarX Appoints Experienced CEO to Accelerate Stabl-Im Brain Cancer Trials
9:04am on Wednesday 29th of April, 2026 AEST
Key Points
Dr Meyrick brings 20+ years in radiopharmaceuticals and clinical development
Stabl-Im platform targets safe, non-invasive brain cancer imaging via MRI
Advanced CRO negotiations underway for first-in-human trials in 2026
CEO remuneration tied to clinical milestones and regulatory progress
Read Story
middle.
Tap to Read
Tap the card to read the full analysis
about
Trivarx (ASX:TRI)
OPEN ARTICLE